Shandong Sito Bio-technology Co Ltd (300583.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002F36

Price
11.37 CNY
Market cap
2.16 bn CNY
P/E (2025)
–
P/S (2025)
2.12
Dividend yield
0.04 %
Net margin
-7.19 %
Return on equity (ROE)
-4.15 %
Return on assets (ROA)
-2.47 %

Shandong Sito Bio-technology Co Ltd financials

Fiscal year20242025
Revenue970.60 m CNY1.02 bn CNY
Gross profit108.10 m CNY152.55 m CNY
Operating income-102.06 m CNY3.50 m CNY
EBIT-67.51 m CNY-48.04 m CNY
Net income-88.77 m CNY-73.15 m CNY
Diluted EPS – continuing operations-0.47 CNY-0.39 CNY

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Shandong Sito Bio-technology Co Ltd

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. It also provides APIs for animal health, including neomycin sulfate and tylosin tartrate. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.